CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure
Abstract. Invasive pulmonary aspergillosis (IPA) is a lethal infectious disease with high mortality in patients with liver failure. Early recognition of the risk factors prompting earlier diagnosis and treatment may improve the outcomes. Voriconazole is recommended as the first-line drug for IPA, bu...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health - Lippincott Williams Wilkins
2022-04-01
|
| Series: | Infectious Diseases & Immunity |
| Online Access: | http://journals.lww.com/10.1097/ID9.0000000000000036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210232772329472 |
|---|---|
| author | Chuan Shen Qian Zhao Ziyue Li Wei Wang Yalin Zhao Lingya Kong Jing Xie Caiyan Zhao Wei Zhao |
| author_facet | Chuan Shen Qian Zhao Ziyue Li Wei Wang Yalin Zhao Lingya Kong Jing Xie Caiyan Zhao Wei Zhao |
| author_sort | Chuan Shen |
| collection | DOAJ |
| description | Abstract. Invasive pulmonary aspergillosis (IPA) is a lethal infectious disease with high mortality in patients with liver failure. Early recognition of the risk factors prompting earlier diagnosis and treatment may improve the outcomes. Voriconazole is recommended as the first-line drug for IPA, but hepatotoxicity limits its use in the context of liver diseases. We report a case of a 63-year-old female who was admitted to the Third Affiliated Hospital of Hebei Medical University due to IPA after glucocorticoid therapy for liver failure. The polymorphism of cytochrome P450 (CYP) isoenzymes showed CYP2C19∗1/∗2 genotype associated with intermediate metabolism of voriconazole. However, the patient developed side effects such as skin rash, vomiting, hyperbilirubinemia, and alteration of consciousness, even if she received half of the recommended dosage for voriconazole. Therapeutic drug monitoring (TDM) was applied to guide the dosage adjustment of voriconazole in this patient, and consequently, the patient presented a favorable outcome. In conclusion, genotyping screening plus TDM dependent individualized treatment of voriconazole may improve the survival of liver failure patient with IPA. |
| format | Article |
| id | doaj-art-c44e4c5536a34de3a8bca5d64e0f001d |
| institution | OA Journals |
| issn | 2693-8839 |
| language | English |
| publishDate | 2022-04-01 |
| publisher | Wolters Kluwer Health - Lippincott Williams Wilkins |
| record_format | Article |
| series | Infectious Diseases & Immunity |
| spelling | doaj-art-c44e4c5536a34de3a8bca5d64e0f001d2025-08-20T02:09:48ZengWolters Kluwer Health - Lippincott Williams WilkinsInfectious Diseases & Immunity2693-88392022-04-012212512810.1097/ID9.0000000000000036202204000-00009CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver FailureChuan ShenQian ZhaoZiyue LiWei WangYalin ZhaoLingya KongJing XieCaiyan ZhaoWei ZhaoAbstract. Invasive pulmonary aspergillosis (IPA) is a lethal infectious disease with high mortality in patients with liver failure. Early recognition of the risk factors prompting earlier diagnosis and treatment may improve the outcomes. Voriconazole is recommended as the first-line drug for IPA, but hepatotoxicity limits its use in the context of liver diseases. We report a case of a 63-year-old female who was admitted to the Third Affiliated Hospital of Hebei Medical University due to IPA after glucocorticoid therapy for liver failure. The polymorphism of cytochrome P450 (CYP) isoenzymes showed CYP2C19∗1/∗2 genotype associated with intermediate metabolism of voriconazole. However, the patient developed side effects such as skin rash, vomiting, hyperbilirubinemia, and alteration of consciousness, even if she received half of the recommended dosage for voriconazole. Therapeutic drug monitoring (TDM) was applied to guide the dosage adjustment of voriconazole in this patient, and consequently, the patient presented a favorable outcome. In conclusion, genotyping screening plus TDM dependent individualized treatment of voriconazole may improve the survival of liver failure patient with IPA.http://journals.lww.com/10.1097/ID9.0000000000000036 |
| spellingShingle | Chuan Shen Qian Zhao Ziyue Li Wei Wang Yalin Zhao Lingya Kong Jing Xie Caiyan Zhao Wei Zhao CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure Infectious Diseases & Immunity |
| title | CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure |
| title_full | CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure |
| title_fullStr | CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure |
| title_full_unstemmed | CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure |
| title_short | CYP2C19 Genotyping Plus Therapeutic Drug Monitoring Dependent Voriconazole Treatment for Invasive Pulmonary Aspergillosis in a Patient with Liver Failure |
| title_sort | cyp2c19 genotyping plus therapeutic drug monitoring dependent voriconazole treatment for invasive pulmonary aspergillosis in a patient with liver failure |
| url | http://journals.lww.com/10.1097/ID9.0000000000000036 |
| work_keys_str_mv | AT chuanshen cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT qianzhao cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT ziyueli cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT weiwang cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT yalinzhao cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT lingyakong cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT jingxie cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT caiyanzhao cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure AT weizhao cyp2c19genotypingplustherapeuticdrugmonitoringdependentvoriconazoletreatmentforinvasivepulmonaryaspergillosisinapatientwithliverfailure |